Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:34 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS/CANDLE, SAVI, and AGS
NCT04517253 · Eli Lilly and Company · PHASE2/PHASE3 · terminated · last registry update 2025-07-10 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study was terminated due to efficacy/effectiveness reasons” | – | Registry record, Eli Lilly and Company |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against JAK1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-07-10Results posted on the registry: Eli Lilly and Company, Baricitinib + TNF Inhibitor (NCT04086745)
- 2026-07-09Results posted on the registry: Massachusetts General Hospital, Ruxolitinib (NCT03427866)
- 2026-07-07Results posted on the registry: Tu Dan, Identify any dose-limiting toxicity (DLT) when ruxolitinib is administered to NSCLC cachexia patients. (NCT04906746)
- 2026-06-30Results posted on the registry: Massachusetts General Hospital, Baricitinib (NCT05189106)
- 2026-06-29Results posted on the registry: University of Texas Southwestern Medical Center, Tofacitinib 10mg + Temozolomide (NCT05326464)
- 2026-06-26Also stopped (terminated): Incyte Corporation, itacitinib (NCT04640025)
- 2026-06-24Results posted on the registry: Eli Lilly and Company, Baricitinib + TNF Inhibitor (NCT03915964)
- 2026-06-04Results posted on the registry: Constellation Pharmaceuticals, Pelabresib + Ruxolitinib (NCT02158858)
- 2026-06-03Phase 3 first posted: Takeda, Placebo + Elritercept (NCT07623161)
- 2026-06-01Phase 3 first posted: Sun Pharma Japan Limited, Deuruxolitinib + Placebo (NCT07617597)
- 2026-05-22Results posted on the registry: Incyte Corporation, Ruxolitinib Cream + Vehicle Cream (NCT06238817)
- 2026-05-20Phase 3 first posted: The Affiliated People's Hospital of Ningbo University, Lisaftoclax (APG-2575) (NCT07597941)
- 2026-05-20Also stopped (terminated): Psoriasis Treatment Center of Central New Jersey, Upadacitinib (NCT06773403)
- 2026-05-19Results posted on the registry: Emma Guttman, PF-06700841 + Placebo (NCT05076006)
- 2026-05-19Phase 3 first posted: The Children's Hospital of Zhejiang University School of Medicine, Ruxolitinib 1.5% Cream BID (NCT07595939)
- 2026-05-15Phase 3 first posted: Institute of Hematology & Blood Diseases Hospital, China, Ruxolitinib (NCT07588945)
- 2026-05-12Results posted on the registry: Incyte Corporation, INCB000928 + ruxolitinib (NCT04455841)
- 2026-05-06Phase 3 first posted: GlaxoSmithKline, Momelotinib + Glucocorticoids (NCT07569081)
- 2026-05-06Also stopped (terminated): Mats Remberger, Decidua Stroma Cells (DSC) + Best available Treatment (BAT) (NCT04118556)
- 2026-05-05Phase 3 first posted: Mesoblast, Ltd., Remestemcel-L-rknd (NCT07568535)
- 2026-04-28Phase 3 first posted: Alfasigma S.p.A., Filgotinib (NCT07554495)
- 2026-04-28Results posted on the registry: Milton S. Hershey Medical Center, Ruxolitinib 1.5% Cream (NCT04414514)
- 2026-04-28Also stopped (terminated): Milton S. Hershey Medical Center, Ruxolitinib 1.5% Cream (NCT04414514)
- 2026-04-27Phase 3 first posted: Alfasigma S.p.A., Filgotinib (NCT07553182)
- 2026-04-24Results posted on the registry: Ohio State University Comprehensive Cancer Center, Liposome-encapsulated Daunorubicin-Cytarabine + Ruxolitinib (NCT03878199)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision